A group of European experts are carrying on a study in order to evaluate the efficiency of the Biodegradable stents for benign refractory oesophageal stenosis.
This evaluation is carried on by EUnetHTA partners.
EUnetHTA , the European Network of Health Technology Assessment agencies is a collaboration between 54 European HTA agencies. Further information is available on : www.eunethta.eu
The main focuses of this study are :
– to determinate the current use of this technology (stents),
– to describe the technical characteristics of the treatment,
– to evaluate the safety and the clinical effectiveness of the treatment.
The final report of this study will guide the decision to reimburse or not this surgical treatment.
The group is calling for one or two patient volunteers as “experts of their disease”. Patients with benign refractory esophageal stenosis, parents of a child/teenager with this condition are all concerned by this call.
These volunteers will join the expert panel and will be asked to review the evaluation report in order to bring forwards the patient perspective.
The expert patients need to be good English readers (the report will be written in English). Comments could be formulate in their own languages.
During this evaluation, all the discussions will be confidential and will be covered by an undertaking of confidentiality made by the members of the expert panel.
The evaluation started on 17 March and will continue until 5 December 2014. It will be conducted via e-mails.
The patient participation in this survey is essential to get a full and fair report in collaboration with every other stakeholder (healthcare professionals, industrial and political decision makers).
If you are interested or would like to know more, pleased feel free to contact François Houÿez (Treatment Information and Access Director / Health Policy Advisor, Eurordis) who also represents Rare Diseases in EUnetHTA.
mail: francois.houyez@eurordis.org